IPSS
| 0 | 0,5 | 1 | 1,5 | 2 | |
| Luuytimen blastimäärä (%) | <5 | 5-10 | - | 11-20 | 21-30** |
| Karyotyyppi |
Pieni riski normaali -Y ainoana 5q- ainoana 20q- ainoana
|
Keskikorkea riski muut poikkeavuudet |
Suuri riski ≥ 3 poikkeavuutta kromosomin 7 mikä tahansa poikkeavuus
|
||
| Sytopeniat* | ei yhtään tai 1 | 2 tai 3 | |||
|
*Hb<100 g/L; B-Neutr<1,5x109/L; tromb<100x109/L **Nykyisen WHO-luokituksen mukaan ei enää MDS, vaan akuutti leukemia |
|||||
Keskimääräinen elinaika diagnoosista ja aika transformaatioon AML:ksi (vuosia)
| IPSS-pisteet | Riskiluokka | Potilaita (%) |
Ikä ≤ 70v Elinaika |
Ikä > 70v Elinaika |
Aika, jossa 25%:lle AML-evoluutio (v) |
| 0 | matala | 31 | 9,0 | 3,9 | 9,4 |
| 0,5-1 | keskikorkea-1 | 39 | 4,4 | 2,4 | 3,3 |
| 1,5-2 | keskikorkea-2 | 22 | 1,3 | 1,2 | 1,1 |
| ≥ 2,5 | korkea | 8 | 0,4 | 0,4 | 0,2 |
WPSS-ennusteluokitus
|
|||||||||||||||||||||||||
NOTE. Risk groups were as follows: very low (score = 0), low (score = 1), intermediate (score = 2), high (score = 3 to 4), and very high (score = 5 to 6).
Abbreviations: MDS, myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; 5q–, myelodysplastic syndrome with isolated del(5q) and marrow blasts less than 5%; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB-1, refractory anemia with excess of blasts-1; RAEB-2, refractory anemia with excess of blasts-2.
* Karyotype was as follows: good: normal, –Y, del(5q), del(20q); poor: complex (≥ three abnormalities), chromosome 7 anomalies; and intermediate: other abnormalities.
† RBC transfusion dependency was defined as having at least one RBC transfusion every 8 weeks over a period of 4 months.